Growth-signal inhibition may release a brake on protein kinase B and limit cell death
In cells and tissues, inhibiting mechanistic target of rapamycin complex 1 may restore a brief protein kinase B response that prevents cell death without mitophagy. Protection persisting after selective removal of this response, or a response that increases damage, would reject the hypothesis.
Stage of verification
- Hypothesis published2026-09-30
- Indirect evidenceAssessed at 4 of 10
- Direct testAwaited
Map of the hypothesis
Hover over an icon or tap it to see its name.
Where in the body
Ageing mechanism
Lens
Kind of knowledge gap
A double ring marks the main placement where a group contains several values.
Target map
Every target of every published hypothesis, each with the actions a hypothesis can propose on it. The targets and the actions of this hypothesis are drawn solid.

Enzyme
mTOR
A protein whose suppression reduces excessive transcription of ribosomal genes in the proposed pathway
Where this hypothesis actsCells in several organs exposed to repeated stress, including when mitophagy is blocked
Hypotheses on this target 4
Inhibition4
Activation
Lower level
Higher level
Replacement
Protection from degradation
Cofactor removal
Synthesis suppression
Function preservation

What is proposed
Inhibition
Suppress mTORC1 to restore the brief protective AKT response
With whatNot stated in the record
HowNot stated in the record
Possible result
Possible reduction in stress-induced apoptosis and slower functional deterioration across several systems
From the recordПодавление mTORC1 ослабляет тормозящую связь через киназу S6K и субстрат инсулинового рецептора IRS1

Enzyme
AKT
A protein kinase involved in cellular responses to stress and the regulation of apoptosis
Where this hypothesis actsReceiving cells in several organs during ordinary or repeated stress under mTOR suppression
Hypotheses on this target 1
Inhibition
Activation1
Lower level
Higher level
Replacement
Protection from degradation
Cofactor removal
Synthesis suppression
Function preservation

What is proposed
Activation
Restore the brief protective response to ordinary stress
With whatNot stated in the record
HowSuppress mTORC1 to weaken inhibitory feedback through S6K and IRS1; test necessity by selectively eliminating the additional AKT response
Possible result
Possible reduction in the transition from reversible cellular stress to apoptosis
From the recordвосстанавливается кратковременный защитный ответ протеинкиназы AKT на обычную нагрузку.
All targets of the lab
Every target read from the published hypotheses, each kind around its pictogram. A larger mark means more hypotheses act on that target. Point at a mark and the actions proposed on it branch out of it.
Solid and named: the targets of this hypothesis
Explore in depth
The logic
The train of thought that ends in this hypothesis. Each stage is the reason the next exists. The master question narrows to a goal, the goal to an unknown nobody has closed, the unknown to the hypothesis proposed here. Every step below says what it rests on and what carries it.
A treatment might slow decline in several organs by making their cells less likely to die under the same strain. The unexpected move is to leave damage spreading between organs while changing how receiving cells respond to it. This is a proposal generated by the pipeline, not a measured result.
- Suppression of the growth-regulating mTORC1 assembly weakens the proposed S6K–IRS1 feedback brake.
- Release of that brake changes AKT from a blunted response to a brief response during ordinary strain.
- The restored AKT response is proposed to keep reversible cell stress from progressing to controlled cell death.
- Fewer receiving cells die under the same incoming strain, even while damage continues to pass between organs.
- Reduced cell loss is proposed to slow functional decline in several systems even when selective disposal of mitochondria is blocked.
Several buildings could suffer less from the same electrical surge if their protective switches worked again. The disturbance could still travel through the shared wiring.
Where the picture breaks: Cells do not have a single protective switch, and AKT affects more than survival. The picture does not establish that restoring its response protects every tissue or extends life.
- Master questionstep 01 of 04
Ageing processes may reinforce one another, making a shared cause a possible target for benefits across several bodily systems.
Rests on: The goal takes mutually reinforcing ageing processes as the reason to search for a shared intervention point.
AssumptionThe starting premise assumes that a shared causal link exists and can be changed in a way that benefits several systems; the supplied goal does not establish either condition.
- Goal pillarstep 02 of 04
The search should produce several life-extension ideas with distinct causal explanations.
Rests on: The master question explicitly requests ideas for interventions acting on shared causes of ageing.
Stated in the chain - Gap questionstep 03 of 04
Longer life after suppressing the mechanistic target of rapamycin, or mTOR, a protein that helps regulate cellular growth, might survive blockade of mitophagy, the selective disposal of mitochondria, the cell structures that supply usable energy. The question allows damage to keep spreading between bodily systems and asks whether postponing just one cause of death could explain the entire survival benefit.
Rests on: The search for a shared cause requires distinguishing benefits across several systems from postponement of one fatal condition.
LeapNeither the preceding goal nor the supplied source material establishes the specific starting relationship among mTOR suppression, longer life and mitophagy as its proposed necessary intermediary. That relationship is introduced here as the setting for the question.
- Hypothesisstep 04 of 04
Suppressing mechanistic target of rapamycin complex 1, or mTORC1, a growth-regulating protein assembly, is proposed to loosen a feedback brake involving S6 kinase, or S6K, an enzyme that modifies other proteins, and insulin receptor substrate 1, or IRS1, a protein that relays insulin signals. This would restore a brief response from protein kinase B, also called AKT, an enzyme involved in cell-survival signalling. The response is proposed to keep recoverable stress from becoming apoptosis, a controlled cell-death process, in several organs without requiring mitophagy or reduced damage transmission.S1S3S6
Rests on: The gap question permits protection that does not require mitophagy. S1, in Cellular Physiology and Biochemistry (2015), reports restored AKT activation after mTORC1 inhibition in rainbow-trout liver cells exposed to excess amino acids, the building blocks of proteins; it does not establish protection from cell death or effects across organs. S3, in The Journal of Biological Chemistry (2013), recounts earlier evidence for an S6K–IRS1 feedback brake on AKT signalling under nutrient overload; it does not test the proposed restoration of brief protection during ordinary stress.
Supported by literature
What is carried, and what is not. The cited sources support parts of the feedback-brake explanation and restoration of AKT activity in particular experimental settings, with the limits stated above. They do not establish the full sequence from a brief protective response to reduced cell death, independence from mitophagy, preserved function across organs and longer life.
Where the reasoning is carried by something unstated · 2
- Master question. The starting premise assumes that a shared causal link exists and can be changed in a way that benefits several systems; the supplied goal does not establish either condition.
- Gap question. Neither the preceding goal nor the supplied source material establishes the specific starting relationship among mTOR suppression, longer life and mitophagy as its proposed necessary intermediary. That relationship is introduced here as the setting for the question. Establish the missing link before relying on this step.
How a result here could mislead · 3
- Loss of protection after completely disabling AKT could be mistaken for proof that the treatment's additional AKT response is necessary, although disabling AKT can itself injure cells. What closes it: The intervention must selectively remove the treatment-induced additional response while preserving baseline AKT function. The supplied design explicitly requires this distinction, alongside comparable mTOR suppression.
- A changed light-based signal from a mitochondrial marker could be mistaken for successful blockade of mitophagy. One supplied rival explanation says acidity can change that signal without changing disposal of whole mitochondria. What closes it: Actual mitochondrial disposal must be checked independently of an acidity-sensitive signal, and acidity must be measured alongside it. The supplied testability description does not specify this verification.
- Longer survival or a smaller damage peak could be credited to lower sensitivity of receiving cells even if treatment instead reduces the incoming insult or postpones one fatal disease. What closes it: Protection must be assessed across several systems under comparable incoming strain, with causes of death distinguished. The combined-strain prediction must be fixed from the separate weak-strain responses before the combined test, as the proposal specifies; selective removal of the additional AKT response must also erase the claimed protection.
What would make this wrong. The proposed explanation would fail if protection persisted after verified selective removal of the treatment-induced additional AKT response, with baseline cell function and mTOR suppression preserved. It would also fail if the restored response increased damage rather than limiting it. These are rejection conditions stated in the proposal, not reported observations.
What it would change. If the proposal held, a shared intervention could protect several systems by reducing their cells' susceptibility to death while leaving damage transmission between organs intact. The search for a common ageing target would therefore need to distinguish reduced damage production or spread from reduced harm in receiving cells. Even then, the supplied material would not establish longer life, benefit in humans or the duration of protection; it also does not define the internal outcome label SPV_11 well enough to interpret its claimed stabilisation.
Sources read · 9
Amino Acids Attenuate Insulin Action on Gluconeogenesis and Promote Fatty Acid Biosynthesis via mTORC1 Signaling Pathway in trout Hepatocytes. · Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology · 2015
“mTORC1 inhibition not only inhibited the phosphorylation of mTORC1 downstream targets, but also blunted IRS-1 Ser(302) phosphorylation and restored excessive AAs-suppressed Akt phosphorylation.”
Does not settle: Источник описывает первичные гепатоциты радужной форели при избытке аминокислот и остром воздействии рапамицина. Он не устанавливает защиту от апоптоза, роль митофагии, межорганную передачу повреждения, SPV_11 или эффект в нескольких органах.
Mechanisms of high-glucose/insulin-mediated desensitization of acute insulin-stimulated glucose transport and Akt activation. · American journal of physiology. Endocrinology and metabolism · 2008
“Treatment with rapamycin [a specific inhibitor of mammalian target of rapamycin complex 1 (mTORC1)] inhibited the increased PTEN expression and partially restored insulin-stimulated glucose transport and Akt activation to insulin-resistant cells.”
Does not settle: Источник описывает 3T3-L1 адипоциты с индуцированной высокой глюкозой и низкой дозой инсулина. Он не исследует апоптоз, обратимость клеточного стресса, митофагию, межорганную передачу повреждения, SPV_11 или эффект в нескольких органах. Причинную роль связи S6K-IRS1 в восстановлении AKT он также не устанавливает.
Insulin activates RSK (p90 ribosomal S6 kinase) to trigger a new negative feedback loop that regulates insulin signaling for glucose metabolism. · The Journal of biological chemistry · 2013
“We previously demonstrated that the mTORC1/S6K1 pathway is activated by insulin and nutrient overload ( e.g. amino acids (AA)), which leads to the inhibition of the PI3K/Akt pathway via the inhibitory serine phosphorylation of IRS-1, notably on serine 1101 (Ser-1101).”
Does not settle: Источник не исследует подавление mTORC1, восстановление кратковременного ответа AKT на обычную нагрузку, апоптоз, митофагию, межорганную передачу повреждения, SPV_11 или вероятность гибели клеток в нескольких органах.
Proline-rich Akt substrate of 40-kDa contains a nuclear export signal. · Cellular signalling · 2013
“Finally, A14 cells expressing the NES-mutant showed impaired activation of components of the Akt-pathway as well as of the mTORC1 substrate p70 S6 kinase after insulin stimulation.”
Does not settle: Источник не проверяет подавление mTORC1, связь S6K-IRS1, защитный ответ AKT при нагрузке, апоптоз, митофагию, межорганную передачу повреждения или SPV_11.
Resolvin E1 protects against doxorubicin-induced cardiotoxicity by inhibiting oxidative stress, autophagy and apoptosis by targeting AKT/mTOR signaling. · Biochemical pharmacology · 2020
“The AKT/mTOR signaling pathways were responsible for RvE1-mediated regulation of DOX-induced oxidative stress, autophagy and myocardial apoptosis.”
Does not settle: Источник не устанавливает роль тормозящей связи mTORC1–S6K–IRS1, кратковременное восстановление AKT при обычной нагрузке, необязательность митофагии, межорганную передачу повреждения, SPV_11 или снижение вероятности гибели клеток в нескольких органах.
The mechanism of nickel-induced autophagy and its role in nephrotoxicity. · Ecotoxicology and environmental safety · 2024
“autophagy promotion with rapamycin relieved cytotoxicity and decreased apoptosis.”
Does not settle: This abstract reports a result in TCMK-1 cells exposed to NiCl2. It does not establish mTORC1-S6K-IRS1 feedback, transient AKT protection during ordinary stress, mitophagy independence, effects across organs, or SPV_11 stabilization.
Selaginella tamariscina Inhibits Glutamate-Induced Autophagic Cell Death by Activating the PI3K/AKT/mTOR Signaling Pathways. · International journal of molecular sciences · 2022
“STE strongly inhibited glutamate-induced autophagy by activating the PI3K/Akt/mTOR signaling pathway.”
Does not settle: Работа на мышиной клеточной линии HT22 при глутаматной нагрузке не проверяет ингибирование mTORC1, связь S6K-IRS1, межорганную передачу повреждения или SPV_11.
Pan-cancer oncolytic virotherapy through disruption of tumor cell mitochondrial dynamics. · Molecular therapy : the journal of the American Society of Gene Therapy · 2026
“Concurrently, viral infection serves as the decisive precipitating event that shifts the cellular response from adaptive mitophagy to mitochondrial catastrophe by enhancing complex I and V activities to promote ATP biosynthesis, thereby culminating in acute cell death characterized by a precipitous decline in mitochondrial mass and ATP bioavailability.”
Does not settle: The abstract does not establish mTORC1-S6K-IRS1 feedback, restoration of a transient AKT response to ordinary stress, protection from apoptosis, mitophagy independence, inter-organ damage transfer, or SPV_11 stabilization.
Role of AMBRA1 in mitophagy regulation: emerging evidence in aging-related diseases. · Autophagy · 2024
“AMBRA1 activity is suppressed by the MTOR complex MTORC1 phosphorylation on Ser52 [ ].”
Does not settle: Источник не устанавливает связь подавления mTORC1 с S6K, IRS1 или кратковременным защитным ответом AKT, не оценивает апоптоз при одинаковой нагрузке в нескольких органах и не проверяет независимость эффекта от митофагии.
The gap this hypothesis explains
Two live hypotheses pull in opposite directions here, and the field has not chosen between them.
Does blocking a growth-control protein still extend mouse life when damaged cell powerhouses cannot be cleared?
Original wording · exactly as the pipeline generated it
Сохранится ли продление жизни при подавлении mTOR после выключения предполагаемого посредника, митофагии, если межсистемное усиление повреждений останется прежним, а весь выигрыш объяснит отсрочка одной причины смерти?
What this question is asking
The question asks whether removing damaged energy-producing structures inside cells is necessary for a treatment to extend mouse life. It concerns suppression of mammalian target of rapamycin (mTOR), a protein involved in controlling cell growth, after disabling mitophagy, the process that removes those structures. The relevant comparison is whether suppression still increases remaining lifespan relative to no suppression when this removal process is disabled, compared with when it remains available. The question also considers a conditional explanation: damage in different body systems might continue to worsen other systems' damage, while the entire survival benefit comes from postponing just one cause of death.
- Mammalian target of rapamycin (mTOR)
- A protein involved in controlling cell growth. Suppression means reducing its activity; the question asks whether the resulting lifespan effect requires removal of damaged cellular powerhouses.
- Mitochondria
- Structures inside cells involved in producing usable energy, described here as cellular powerhouses. Their removal is the proposed link between treatment and longer life.
- Mitophagy
- The cellular process that removes mitochondria, including damaged ones. The question treats it as a possible necessary step in the lifespan effect, which the supplied sources do not establish.
- Autophagy
- The broader cellular process for removing and recycling material within cells. Mitophagy is the mitochondria-focused form; a finding about the broader process does not automatically establish the particular role of mitophagy.
- Mediator and mediation
- A mediator is an intermediate process through which an intervention causes an outcome. Here, mediation would mean that suppression of mTOR extends life through its effect on mitophagy, rather than the two simply being associated.
- Intersystem damage amplification
- The proposed process in which damage in one body system worsens damage in another. Its persistence during treatment is a condition considered by the question, not a finding established by the supplied sources.
- Rapamycin
- The treatment evaluated in the mouse lifespan findings quoted in S2. Those findings describe survival responses but do not establish the proposed role of mitophagy.
- Corylin
- The compound studied in S3. The supplied quotation reports a lifespan benefit in female mice without a comparable benefit in males.
- Median lifespan
- The time by which half of a studied group has died. It summarizes survival and does not identify which causes of death changed.
- Survival rate at a stated age
- The proportion of a group still alive at that age. S3 reports a comparison at 125 weeks; the supplied quotation does not give the underlying proportions.
- Mouse strain
- A mouse breeding line with a particular inherited background. S2 reports that strain influences the size of the lifespan response.
- Kisspeptin-10
- The molecule used in S5 to stimulate cellular removal processes. The supplied quotation describes a route independent of mTOR, so it does not establish mediation of a treatment that suppresses mTOR.
- Cellular signaling
- Processes through which activity in one part of a cell changes activity elsewhere in it. A signaling connection alone does not establish an effect on whole-animal lifespan.
- Human neuronal cell line
- Human cells maintained in laboratory culture and used to study nerve-cell processes. Findings in these cells do not by themselves establish survival effects in an animal.
- Hippocampus and cultured hippocampal tissue
- The hippocampus is a brain region. Cultured hippocampal tissue is tissue from that region maintained outside the animal; S5 includes this preparation alongside cell cultures and aging rats.
mTOR suppression is associated with longer mouse survival, mitophagy is its proposed cellular mediator, and the survival gain might occur with unchanged intersystem damage amplification because only one cause of death is delayed.
The proposed explanation places removal of damaged cellular powerhouses between blocking a growth-control protein and longer life. It contrasts protection across several body systems with a scenario in which damage still spreads between systems but one fatal condition occurs later. Establishing these links would distinguish a shared protective process from a narrower explanation of longer survival.
S2 reports generally favorable mouse lifespan findings for rapamycin, and S3 reports longer life in female mice receiving corylin. Neither supplied quotation establishes that removal of damaged cellular structures mediates those benefits. S5 instead reports stimulation of that removal through a route independent of mTOR; it does not establish the proposed mediation. None of the supplied sources establishes unchanged damage amplification between systems or a survival gain fully explained by delaying one cause of death. Those last conditions are hypothetical in the question, and this background-focused selection is too limited to establish or refute the complete premise.S2S3S5
The same question asked without the part nothing read establishes:
- Does suppressing the growth-control protein extend mouse life when removal of damaged cellular powerhouses is disabled?
- Does longer mouse life under suppression of the growth-control protein reflect lasting benefits across several body systems or postponement of one cause of death?
- The lifespan benefit persists Under the question's assumption that removal of damaged cellular powerhouses has been disabled, a persisting benefit would mean that this removal is not necessary for the entire survival effect. If postponement of one cause of death accounts for all of that benefit, longer life would not by itself demonstrate protection across several body systems.
- The lifespan benefit disappears Losing the benefit would be consistent with the removal process being necessary for the survival effect in the stated conditions. That result alone would still not establish that the process protects several systems or interrupts damage spreading between them.
- The lifespan benefit becomes smaller A smaller benefit would be consistent with the removal process contributing to, but not fully accounting for, longer survival. The remaining benefit would still need to be distinguished from the question's alternative explanation of postponing one cause of death.
The proposed explanation links suppression of the growth-control protein to removal of damaged cellular structures, then to lasting benefits across several body systems, and finally to longer life. Each connection matters because longer survival alone does not establish the preceding steps. Under the question's alternative explanation, postponing one fatal disease could extend life while damage elsewhere continues. Mistaking that outcome for protection across several systems would overstate what the survival findings establish.
Подавление mTOR уровня RL-2 связано с мышиной выживаемостью; митофагическое посредничество уровня RL-1 показано на клетках.
Выигрыш оставшейся жизни должен сопровождаться устойчивой пользой нескольким системам и проверенным общим посредничеством за единый горизонт наблюдения.
Не установлено, объясняет ли митофагия многосистемный выигрыш жизни; подавление отдельной смертельной патологии может воспроизводить наблюдаемую выживаемость.
The mechanism it proposes
The engine's own statement of the hypothesis, in full.
Подавление mTORC1 ослабляет тормозящую связь через киназу S6K и субстрат инсулинового рецептора IRS1, благодаря чему восстанавливается кратковременный защитный ответ протеинкиназы AKT на обычную нагрузку. Этот ответ ограничивает переход обратимого клеточного стресса в апоптоз. Митофагия для такого эффекта необязательна. Межорганная передача повреждения может сохраняться, тогда как вероятность гибели клеток при одинаковом входящем воздействии снижается в нескольких органах. Стабилизация SPV_11 возникает за счёт меньшей чувствительности принимающих клеток к нагрузке.
Testing and possible results
The prediction that would tell it apart
A hypothesis that predicts what its rivals predict is not worth running an experiment over. This is the observation on which this one differs.
После блокады митофагии сохраняются краткий ответ AKT, уменьшение апоптоза после повторной нагрузки и замедление функционального ухудшения нескольких систем. Избирательное устранение вызванного лечением ответа AKT отменяет эти эффекты при сопоставимом подавлении mTOR. Модель, построенная по ответам на одиночные слабые нагрузки, заранее предсказывает меньший пик повреждения при их сочетании. Если защита сохраняется при устранённом ответе AKT либо измеренный ответ усиливает повреждение, гипотеза отвергается.
States a measurable outcome; comparing rivals needs more conditions. The prediction states observable persistence and loss of effects, a qualitative damage comparison, and explicit rejection conditions. No rival prediction is supplied. Only a bench experiment would settle it.
What testing it would take
The engine's own read on whether this is testable with methods that already exist.
Временные ряды фосфорилирования и апоптоза доступны в клетках и тканях. Проверка необходимости требует вмешательства, устраняющего именно дополнительный ответ AKT: полное выключение AKT само по себе повреждает клетки и делает результат неоднозначным.
Other explanations
Every other hypothesis the engine wrote for the same gap, and the observation that would separate the two.
После блокады митофагии сохраняются краткий ответ AKT, уменьшение апоптоза после повторной нагрузки и замедление функционального ухудшения нескольких систем. Избирательное устранение вызванного лечением ответа AKT отменяет эти эффекты при сопоставимом подавлении mTOR. Модель, построенная по ответам на одиночные слабые нагрузки, заранее предсказывает меньший пик повреждения при их сочетании. Если защита сохраняется при устранённом ответе AKT либо измеренный ответ усиливает повреждение, гипотеза отвергается.
- What would separate them
Rapamycin may extend life by changing calcium control of breathing-muscle contraction predicts: При подтверждённой блокаде митофагии рапамицин сохраняет выигрыш оставшейся жизни и повышает устойчивость диафрагмы к повторным сокращениям. Сопоставимое подавление mTOR генетическим способом этого результата не воспроизводит. Лиганд FKBP12, сохраняющий необходимое кальциевое действие и не подавляющий mTOR, воспроизводит оба эффекта. Избирательное устранение кальциевого действия рапамицина отменяет выигрыш при сохранённом подавлении mTOR. Сохранение пользы генетического подавления mTOR после такого устранения опровергает гипотезу.
- Rival 02 of 04What would separate them
Lysosomal acidity may mimic faster mitochondrial removal predicts: Изменение сигнала mt-Keima объясняется независимо измеренной кислотностью и количеством ранее накопленного репортёра. После соответствующей калибровки увеличение потока исчезает; независимое отслеживание доставки и разрушения меченых митохондрий также не выявляет ускорения. При этом подавление mTOR замедляет рост опухоли даже после устранения дополнительных механизмов остальных гипотез. Длительные траектории заранее выбранных неопухолевых функций остаются прежними. Подтверждение ускоренного удаления целых митохондрий независимыми методами опровергает оптическую часть гипотезы.
- What would separate them
Reducing ribosomal gene transcription may protect tissues by limiting genome damage predicts: При подавленной митофагии лечение уменьшает гибриды РНК и ДНК и новые разрывы в рибосомных генах до появления функциональной пользы. Направленное удаление патологических гибридов рибонуклеазой H1 воспроизводит защиту и уменьшает дополнительный эффект рапамицина в диапазоне, свободном от потолочного эффекта. Избирательное восстановление исходного уровня гибридов при сохранённом подавлении mTOR отменяет защиту. Если лечение сохраняет функциональную и жизненную пользу при экспериментально восстановленном геномном повреждении, эта версия отвергается.
- Rival 04 of 04What would separate them
Ubiquitin-dependent protein disposal may preserve tissue function despite defective mitophagy predicts: После выключения митофагии сохраняются ускоренное разрушение заранее меченых повреждённых цитозольных белков и функциональная польза. Устранение именно вызванного лечением прироста убиквитин-зависимого разрушения отменяет пользу, хотя подавление mTOR и изменения транскрипции рибосомных генов сохраняются. Независимое восстановление протеасомного потока возвращает защиту. Сохранение пользы при отсутствии дополнительного разрушения соответствующих белков опровергает гипотезу.
What stands behind it
Which of the figures above have a study behind them, which are the engine's own, and what it would take to refute the hypothesis. This audit never judges the idea.
This hypothesis states no figure and cites no study, so there is nothing here to trace.
What it would take to refute it. Nothing already retrieved carries the prediction’s terms and it names no measurement this layer can route to a public dataset, so the bench is the residual — not a finding against it.
0 citation handles extracted; 1 Europe PMC search run; 0 records examined; 0 sources stored for enrichment, 0 with full text. A citation that did not resolve is a bibliographic failure, not proof that no such paper exists, and no hypothesis is blocked by this audit.